Polar Capital Global Healthcare Trust is navigating a volatile year for drugmakers and medical technology groups as US policy risk, Patent cliffs and the obesity-drug boom reshape the sector.
Polar Capital Global Healthcare Trust (LSE:PCGH), the FTSE 250-listed specialist Investment trust focused on healthcare companies worldwide, enters the closing months of its financial year against an unusually complex backdrop for its sector. Healthcare has lagged the broader stock market for much of the period since 2023, as investors chased technology and artificial intelligence beneficiaries, while US drug-pricing policy, Tariff threats and regulatory change have created bouts of Volatility for pharmaceutical shares.
A diversified healthcare portfolio
Managed by Gareth Powell and James Douglas, the trust invests across the full healthcare spectrum, including large pharmaceutical groups, biotechnology firms, medical device and technology makers, healthcare services and insurers, and life science tools suppliers. The managers aim to capture long-term structural growth drivers such as ageing populations, rising chronic disease, innovation in Drug Development and the expansion of healthcare spending in emerging economies, while managing the risks that come from policy and patent cycles.
The sector has been shaped in recent years by the extraordinary rise of GLP-1 obesity and diabetes treatments, which transformed the fortunes of manufacturers such as Novo Nordisk and Eli Lilly and rippled through Supply chains, medical device companies and even food retailers. More recently, competition in that market has intensified and investors have become more discerning about which players can sustain growth.
Policy and valuation crosscurrents
US healthcare policy remains a key swing factor. Measures aimed at lowering drug prices, including efforts to link US prices more closely to those paid in other developed countries, and the threat of tariffs on imported pharmaceuticals have weighed on large-cap pharma valuations at times. At the same time, several big drugmakers face patent expiries on major products over the coming years, increasing their need to acquire innovation from smaller biotechnology companies. That dynamic has historically supported M&A activity across the sector, which can benefit specialist portfolios holding Takeover targets.
Valuations across parts of healthcare now look undemanding relative to the wider market, which some fund managers argue provides a Margin of safety. Healthcare has also traditionally offered defensive characteristics, as Demand for medicines and treatment tends to be resilient through economic cycles. Beyond the large drugmakers, the managers can look to medical technology companies benefiting from recovering procedure volumes, healthcare IT providers and tools suppliers serving drug developers, as well as businesses applying artificial intelligence to diagnostics and drug discovery, areas that broaden the portfolio's sources of return.
Discount and Shareholder considerations
Like many specialist investment trusts, PCGH has traded at a discount to net asset value in recent years, as investor appetite for healthcare funds has cooled. The board has used share Buybacks to help manage the gap. Across the sector, boards have become more proactive about discount control and exit opportunities for shareholders, partly in response to pressure from activist investors and consolidation among Wealth managers, which favour larger, more liquid vehicles.
What to watch
The trust's financial year ends on 30 September, so annual results setting out full-year performance against its global healthcare benchmark, along with the dividend, are expected in the coming months. Investors will also follow developments in US drug pricing policy, the progress of clinical trial readouts across the portfolio, and the pace of sector M&A. A rotation of investor flows back into defensive sectors would be expected to support sentiment towards the trust.






Please wait processing your request...